Status:
COMPLETED
Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19
Lead Sponsor:
Materno-Perinatal Hospital of the State of Mexico
Conditions:
COVID 19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone have the ability to control cytokine storms. This work explores the therapeutic effects of both, on the early treatment of patients with se...
Detailed Description
The therapeutic target of COVID-19 is focused on the control of inflammation and the prevention of fibrosis. Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone have the ability to control cy...
Eligibility Criteria
Inclusion
- patients infected with SARS-CoV-2, hospitalized, with total bilirubin ≤1.5
Exclusion
- if the patient underwent treatment with biological antirheumatic drugs, disease modifiers (DMARDs) or other immunosuppressive agents, patients who required continuous therapy with systemic corticosteroids in a dose greater than 10 mg of prednisone per day or equivalent; pregnant women, calculated creatinine clearance (or estimated glomerular filtration rate less than 10 ml/min or patients requiring renal replacement therapy
Key Trial Info
Start Date :
February 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2024
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT06585319
Start Date
February 1 2020
End Date
August 31 2024
Last Update
September 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Monica Pretelini Saenz Maternal Perinatal Hospital
Toluca, State of Mexico, Mexico, 50120